Novartis’ Entresto’s (sacubitril/valsartan) Likelihood of Approval (LoA) in acute myocardial infarction dropped by 11 points on the heels of the Phase III PARADISE-MI trial not meeting its primary endpoint.
Entresto’s LoA dropped to 18% from 29%, as determined on 7 May, by GlobalData’s analysis using a combination of machine learning and its proprietary algorithm. In PARADISE-MI, Entresto did not meet the primary composite endpoint of reducing risk of cardiovascular death and heart failure events after an acute myocardial infarction, despite there being a trend favouring Entresto against standard-of-care generic ramipril, according to a 27 April media release detailing company guidance for the year.
Go deeper with GlobalData
Topline PARADISE-MI data will be presented on 15 May as a late-breaking abstract at the Virtual American College of Cardiology’s Annual Scientific Session.
Reynald Castaneda is an Associate Editor for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
Related Company Profiles
Novartis AG